Roche's Enspryng Wins European Approval For Spinal Cord, Optic Nerve Inflammation Disorder

  • The European Commission has approved Roche Holding AG's RHHBY injectable Enspryng for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD).
  • The approval for the treatment comes as a monotherapy or in combination with immunosuppressive therapy. 
  • Enspryng is the first and only NMOSD treatment administered subcutaneously every four weeks, allowing home-dosing after appropriate training.
  • The EU approval follows FDA's nod last August to treat the rare condition, also called Devic's disease, where the immune system damages the spinal cord and the nerves of the eyes.
  • Price Action: RHHBY shares are up 0.8% at $46.97 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFDAGeneralBriefsEuropean Medicines Agency (EMA)inflammatory diseasesneuromyelitis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!